newsfilter
← Latest News
Business Wire·

European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

VEVEY, Switzerland & LONDON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy. PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older.